On September 19, 2023 IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, reported significant updates to its foundational IP portfolio (Press release, In8bio, SEP 19, 2023, View Source [SID1234635244]). The company was recently granted patents around the world that cover use of the combination of its proprietary DeltEx DRI platform with CAR-T and CPI’s.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IN8bio’s DRI platform uses genetic engineering to empower gamma-delta T cells with resistance to the killing effects of chemotherapy enabling them to be more effective at killing cancer cells. This innovative approach allows synergistic combinations with standard-of-care chemotherapy regimens to strengthen the immune response and broadly eliminate cancer cells. The technology covered by the newly granted patents enhance the therapeutic potential of DRI cells by enabling their integration with CAR-T technology and CPIs, thereby bolstering the potential effectiveness of the drug therapy against solid tumor cancers.
William Ho, CEO and co-founder of IN8bio, stated, "Establishing a robust IP foundation is pivotal to the successful growth and expansion of our business. Our proprietary DRI technology, which generates chemotherapy-resistant cells, allows for the synergistic combination with front-line chemotherapies to break down barriers preventing a robust immune response. Our technology, supported by these newly granted patents opens avenues for expanding the application of these cells in conjunction with CAR-T technologies and checkpoint inhibitors to advance the fight against cancer. By harnessing these cells, we can bring cell therapy to the forefront of treatment options and offer new hope towards realizing our mission of achieving ‘Cancer Zero,’ our goal of pursuing the safe eradication of all tumor cells in patients fighting cancer."
IN8bio’s DRI platform has enabled a deep pipeline of product candidates. The Company has initiated a Phase 2 clinical trial (NCT05664243) of a genetically modified autologous gamma-delta T cell therapy, INB-400, targeting newly diagnosed glioblastoma (GBM). The trial, cleared by the Food and Drug Administration (FDA) in December 2022, will be conducted at multiple centers across the United States and is open for enrollment. IN8bio is also conducting Phase 1 clinical trials of INB-200 for the treatment of newly diagnosed GBM and INB-100 for the treatment of patients with leukemias undergoing haploidentical stem cell transplantation (HSCT). Clinical updates in both programs are expected to be presented at major medical meetings this fall.
IN8bio boasts a strong IP portfolio of granted patents encompassing the DRI, CAR-T and HSCT families, with multiple additional applications pending globally to further expand its patent portfolio and IP position.